Evidence map›Paper›PMID 41964884›Full record

ArticleWorld journal of urology2026

Years of life lost in squamous cell carcinoma of the penis.

Federico Polverino, Calogero Catanzaro, Michele Nicolazzini, Michele Petix, Leonardo Quarta, Maximilian Filzmayer, Jordan A Goyal, Massimiliano Creta, Simone Morra, Gianluigi Califano and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Federico PolverinoCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada. fedepolve97@gmail.com.ORCID http://orcid.org/0009-0007-6218-3761
Calogero CatanzaroCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Michele NicolazziniCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Michele PetixCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Leonardo QuartaCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Maximilian FilzmayerCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Jordan A GoyalCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Massimiliano CretaDepartment of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.
Simone MorraCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Gianluigi CalifanoDepartment of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.
Claudia Collà RuvoloCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Alberto BrigantiVita-Salute San Raffaele University, Milan, Italy.
Felix K H ChunDepartment of Urology, Goethe University, University Hospital, FrankfurtFrankfurt Am Main, Germany.
Carlotta PalumboDivision of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore Della Carità Hospital, Novara, Italy.
Riccardo SchiavinaDivision of Urology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
Gennaro MusiDepartment of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.
Shahrokh F ShariatDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Fred SaadCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Nicola LongoDepartment of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.
Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSurvival patterns in squamous cell carcinoma of the penis (SCCP) have been described in several studies. However, the years of life lost (YLL) among patients with SCCP compared to the general population have not been quantified.

methodsWithin the SEER database (2004-2021), SCCP patients aged 40-75 years were included. SCCP patients were stratified according to stage at diagnosis in localized (T1-2, N0, M0), regional (T3-4, anyN, M0; anyT, N +, M0), and metastatic (anyT, anyN, M1). For each patient, an age- and sex-mathced control was generated from Social Security Administration life tables using Monte Carlo simulation. Subsequently, the average YLL until the age of 75 years between SEER patient cases and simulated controls were quantified using the Kaplan-Meier methodology.

resultsOverall, 1666 (64.9%) localized, 505 (28.1%) regional and 123 (7.0%) metastatic SCCP patients were included. Relative to population controls, SCCP patients of all-stages exhibited 4.4 YLL (p < 0.001). In subsequent stage stratified analyses YLL values were 3.0 vs. 6.0 vs. 10.7 YLL (p < 0.001) for respectively localized, regional and metastatic SCCP subgroups.

conclusionIn general SCCP patients are at 4.4 YLL relative to population controls, the latter may reach 10.7 YLL when metastatic stage at presentation is diagnosed.

Indexed as

Carcinoma, Squamous CellLife ExpectancyPenile NeoplasmsAdultAgedHumansMaleMiddle AgedNeoplasm StagingSEER ProgramSEER databaseSquamous cell carcinoma of penisSurvivalYears of life lost

Identifiers

PMID41964884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.